Serving Detroit and Metro Detroit. Licensed providers. US pharmacies. Discreet shipping.
GOLDENGLOW
Menopause and Hormones

Does HRT Cause Breast Cancer? What the WHI Study Found

It depends on the type of hormone therapy. In the Women's Health Initiative, estrogen plus progestin was linked to a higher breast cancer risk, while estrogen alone in women without a uterus was linked to a lower risk. Your own risk depends on age, timing and history.

By the Golden Glow editorial teamReviewed November 3, 20261 minute read

It depends on the type of hormone therapy. In the Women's Health Initiative (WHI), the large US trials that shaped menopause care for two decades, estrogen combined with a progestin was linked to an increased risk of breast cancer, while estrogen alone, studied in women who had had a hysterectomy, was linked to a lower risk. Your own risk depends on your age, how long after menopause you start, how long you use therapy, and your personal and family history.

Key takeaways

  • The WHI tested two regimens: estrogen plus progestin, and estrogen alone in women without a uterus.
  • Estrogen plus progestin was associated with more breast cancers; estrogen alone was associated with fewer.
  • The women studied were, on average, in their 60s, older than most women who start therapy for symptoms today.
  • Current guidance says benefits generally outweigh risks for healthy women under 60 or within 10 years of menopause.
  • A family history of breast cancer does not automatically rule out hormone therapy, but it shapes the decision.

What the WHI was and why it mattered

The WHI hormone trials began in the 1990s and enrolled more than 27,000 women. One trial compared conjugated equine estrogens plus medroxyprogesterone acetate (a progestin) with placebo in women with a uterus. The other compared estrogen alone with placebo in women who had had a hysterectomy.

When early results were announced in 2002, headlines focused on breast cancer and heart risk, and hormone therapy use fell sharply. Over the following years, longer follow-up and closer analysis by age group gave a more detailed picture, summarized by the National Cancer Institute.

The two different answers

Estrogen plus progestin: Women in this arm had a higher risk of breast cancer than women on placebo, and the risk rose with longer use. The National Cancer Institute's fact sheet describes this increased risk clearly.

Estrogen alone: In women without a uterus, estrogen alone was associated with a lower risk of breast cancer than placebo during the trial. This result surprised many people and is one reason risk discussions today separate the two regimens.

Neither result applies automatically to every product. The WHI used specific hormones, and many women today use estradiol and micronized progesterone, which were not the hormones tested.

Why age and timing change the picture

The average WHI participant was in her early 60s, many years past menopause. Today, most women considering hormone therapy are in their 40s or 50s and seeking relief from symptoms. The Menopause Society's 2022 position statement concludes that for healthy women under 60 or within 10 years of menopause, the benefits of hormone therapy for bothersome symptoms generally outweigh the risks, and that risks are greater when therapy starts later.

In November 2025 the FDA began removing boxed warning language about cardiovascular disease, breast cancer and probable dementia from hormone therapy labels, and in February 2026 it approved the first six updated labels. The Menopause Society welcomed parts of the change and noted that systemic estrogen still carries risks for some women. Breast cancer risk remains part of the conversation even with new labels.

If breast cancer runs in your family

A family history does not automatically rule out hormone therapy, but it is an important part of the risk review. Your licensed provider will ask who was affected and at what age, and may recommend a specialist assessment, particularly if a hereditary pattern is possible. Women who have had breast cancer themselves are generally not candidates for systemic hormone therapy and need individual advice. Non-hormone options for hot flashes exist and are worth discussing.

Whatever you decide, keep up with recommended mammograms.

Putting risk in perspective

Absolute risk matters more than relative risk. A percentage increase can sound alarming while the change in actual cases per thousand women per year is small. Ask your provider to explain your risk in absolute terms, and to compare it with other everyday risk factors such as alcohol and body weight, which also affect breast cancer risk.

Frequently asked questions

Does estrogen alone increase breast cancer risk?

In the WHI, estrogen alone in women without a uterus was associated with a lower breast cancer risk than placebo. Women with a uterus usually need a progestogen with estrogen, which is why the regimens are discussed separately.

Is progesterone safer than the progestin used in the WHI?

The WHI used medroxyprogesterone acetate, not micronized progesterone. Some observational research suggests differences, but the evidence is not definitive, so your provider will discuss what is known for the specific product.

How long can I take hormone therapy?

There is no single cutoff. Guidance recommends reviewing benefits and risks regularly, at least once a year, with your provider.

Can I take hormone therapy if I have dense breasts?

Breast density is part of your overall risk picture. Tell your provider about your mammogram results so they can factor it in.

Talk to a licensed provider

Breast cancer risk is personal, and a good decision weighs it against how much your symptoms affect your life. Start an online menopause visit and a licensed provider will review your history and explain your options. This article is educational and does not determine eligibility for any treatment.

Sources

  1. National Cancer Institute, Menopausal Hormone Therapy and Cancer
  2. The 2022 hormone therapy position statement of The North American Menopause Society, Menopause (2022)
  3. The Menopause Society comments on the FDA announcement on hormone therapy (Nov 10, 2025)
  4. FDA, FDA approves labeling changes to menopausal hormone therapy products (Feb 12, 2026)

This article is educational and is not medical advice. Golden Glow content is written to be accurate and is reviewed against the sources above. Rx programs require an online visit with a licensed provider. Results vary.

Keep reading

All articles
Longevity

Weight Loss and Longevity for Black Women: What the Research Says

Black women carry a higher burden of obesity and often have longer menopause symptoms, according to CDC and NIH-funded research. Provider-guided GLP-1 care, menopause care and steady habits can support more healthy years, and results vary.

Hair and Skin

Hair Loss in Black Women: Causes, Early Signs and Options

Traction alopecia and CCCA are two common causes of hair loss in Black women, and both are easier to treat early. Pattern thinning at the part or crown may respond to topical minoxidil after a provider review, while scarring types need a dermatologist.

Menopause and Hormones

How Do I Know If I'm in Perimenopause? A Symptom Checklist

Most women recognize perimenopause from a pattern of changes, such as shifting cycles, night sweats, poor sleep and mood changes, usually starting in their 40s. No single test confirms it, so tracking symptoms is the most useful first step.